UK Orphan Drug Access Slammed; Shire Calls For Urgent 'Access Summit'
Executive Summary
Orphan drugs "are falling through the cracks" of the UK’s market access process, Shire's country general manager tells the Pink Sheet and calls for urgent all-party remedial talks.
You may also be interested in...
Lessons From Europe: Orphan Drug Valuations Show Limits Of Cost Effectiveness
Biogen, Sanofi executives says US should learn from experience of European health technology assessment bodies as Institute for Clinical and Economic Review embarks on initiative to adapt its value framework to orphan drugs.
English ministers veto Alexion's ultra orphan Soliris
English health ministers have rejected orphan drugs advisor, AGNSS' recommendation endorsing Alexion's Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS). The ministers want more advice on the drug's affordability and are sending it for review by NICE, despite concerns that the health technology appraisal institute's current methods are unsuitable for drugs for rare conditions.
NICE to adopt orphan drugs
From April 2013, NICE, the health technology appraisal institute for England and Wales, will take on the task of appraising orphan medicines. The news may worry some companies given the criticism levelled at NICE over its assessments of rare and end-of-life cancer treatments. However, it looks likely that NICE will be taking note of existing procedures for assessing such drugs and adapting its processes.